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What was the TRUFFLE study? The Trial of Randomized Umbilical and Fetal Flow in Europe 
(TRUFFLE) was a prospective multicentre, unblinded, randomized trial that ran between Jan 1, 2005 
and Oct 1, 2010 in 20 European centres [1]. It studied singleton fetuses at 26–32 weeks of gestation 
who had very preterm fetal growth restriction (FGR), defined as abdominal circumference (AC) <10th 
percentile and high umbilical artery Doppler pulsatility index (PI) [>95th percentile]. In order to 
assess whether changes in the fetal ductus venosus (DV) Doppler waveform or short-term variation 
(STV) on cardiotocography (CTG) should be used as a trigger for delivery in these pregnancies, we 
randomly allocated the 542 included women to one of three “timing of delivery” plans 
(randomization was 1:1:1).  
What were the three timing of delivery arms? Women were randomized to one of three groups 
that mandated delivery based on either: 
1. CTG STV: an abnormal CTG , defined as a fetal heart rate STV < 3.5 msec between 26
+0
 to 
28
+6
 weeks of gestation or STV <4 msec between 29
+0
 to 31
+6
 weeks gestation; in this group 
the DV was not measured; 
2. Early DV changes: A DV pulsatility index >95th percentile, OR CTG STV below a ‘safety net’ 
level (see box). 
3. Late DV changes: The DV A-wave (the deflection within the venous waveform signifying 
atrial contraction) at or below the baseline. OR CTG STV below the same ‘safety net’ as 
group 2 (see box). 
What was the ‘safety net’? The safety net (see box) reflected fetal monitoring parameters, agreed 
by consensus amongst TRUFFLE investigators, that mandated delivery irrespective of randomized 
group. This safety net applied to all patients, hence if the results of this trial are implemented in 
guidelines or local protocols the safety net criteria must be an integral part of it. In addition, delivery 
could be indicated in all groups based on maternal conditions (chiefly pre-eclampsia).  
Box: Safety net criteria for triggering delivery regardless of randomized group 
STV criteria: 
The cut off ‘rescue’ value of STV for delivering based on CTG at 26
+0
 to <28
+6
 weeks is if STV < 2.6 
msec; and 29
+0
 to <31
+6
 weeks if STV< 3 msec. Or if, irrespective of STV, there are spontaneous 
repeated persistent unprovoked decelerations on CTG.  
Umbilical artery Doppler criteria: 
Absolute indications for delivery in all randomized arms: 
≥32
+0
 weeks deliver if reversed umbilical artery EDF 
≥34
+0
 weeks deliver if absent umbilical artery EDF. 
Delivery may be undertaken according to local policies after 30
+0
 weeks if there is reversed umbilical 
artery EDF, and after 32
+0
 weeks if there is absent umbilical EDF. 
What were the results in the primary outcome of the randomized trial? The primary outcome was 
survival without cerebral palsy or neurosensory impairment, or a Bayley III developmental score of 
less than 85, at 2 years of age.  
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There are two ways to look at the primary outcome: One way is to assess "survival without 
neurological impairment" – in this composite outcome, death is in a sense equivalent to a 
neurologically impaired infant. There was no significant difference in this outcome among all 
pregnancies randomized. But as neurological assessment is only possible in surviving infants, and 
because of this the protocol specified a second way of analysis: one where the primary analysis is 
restricted to surviving infants.  This is also on the grounds that it is an outcome important to 
parents.  On this analysis there were significantly more neurologically intact babies at two years in 
the ‘deliver on late ductus venosus changes with CTG safety net’ group; the proportion without 
neurodevelopmental impairment at 2 years was 85% in the CTG group, 91% in the early ductus 
venosus group and 95% in the late ductus group. This improvement in neurodevelopmental 
outcome was accompanied by a non-significant increase in perinatal and infant mortality. Both 
analyses were included in the main trial report [1].  In clinical practice, ‘deliver on late ductus 
venosus changes with CTG safety net’ is therefore the policy which the TRUFFLE group recommends. 
What were the other findings of the TRUFFLE study? The median gestational age at delivery was 
30.7 weeks (IQR 29.1–32.1) and mean birthweight was 1019 g (SD 322), confirming the severe early 
onset FGR in the women taking part. Despite this severity, outcome were better than often 
reported: over 80% of babies survived and had no demonstrable neurological impairment at 2 years 
of age; 12 fetuses (2%) died in utero despite close monitoring; and 27 (6%) neonatal deaths 
occurred. The cerebral palsy rate was around 1%, much lower than frequently quoted. Nearly three 
quarters of women developed gestational hypertension: in this case the pregnancies proceeded for 
a median of just under one week. If no hypertension developed, the median time from diagnosis to 
delivery was two weeks. 
The bar chart shows the proportion of babies overall with no impairment, impairment or death 
based on gestational age at recruitment: at 26-28 weeks and 29-31 weeks [2]. 
 
X- axis represents randomized groups; CTG = Delivery based on cardiotocogaphy;  DVPI95 = Delivery based on 
DV pulsatility index >95th percentile;  DVnoA = DV A-wave at or below the baseline.  
Were TRUFFLE babies a highly selected sample? Early onset FGR is not common, so in that sense 
yes. But, after excluding those fetuses affected by congenital abnormalities, chromosomal conditions 
and infections (based on a careful ultrasound scan, chromosomal testing where indicated and a 
blood infection screen), most had growth restriction due to utero-placental insufficiency. These 
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investigations are all routinely carried out in European fetal medicine settings and are applicable to 
any such setting. It should be noted that there is a group of even more severe early FGR - such that 
fetuses were not eligible for the study, for example due to not fulfilling the inclusion criteria for DV 
PI or STV. Consequently, the conclusions of the study should be used with caution in such fetuses. 
Are the TRUFFLE results generalizable? They are generalizable to settings where there is specialist 
fetal medicine expertise with ability to undertake arterial and venous Doppler assessments regularly; 
where computerised CTG (cCTG) is available; and where high level neonatal facilities exist. 
Why was the prevalence of adverse outcomes in TRUFFLE lower than anticipated? The better than 
expected outcomes probably reflected the benefit of being in a trial and being closely looked after 
by expert obstetric teams, and expert neonatal care.  It suggests and that clinical care in early onset 
growth restriction should be undertaken in tertiary level units or other centres of excellence. In 
addition, it has been shown in many studies that joining trials is of benefit (even in those where an 
intervention proves ineffective) and this may have had a role to play [3]. 
Neurological outcome at 2 years of age was better in the late DV group. Does this mean I can 
manage these pregnancies with Doppler and without cCTG? No. The timing of delivery plan in the 
late DV group consisted of a package, which included cCTG at ‘safety net’ level alongside DV 
Doppler. In this context it should not be forgotten that in the DV groups twice as many fetuses were 
delivered on the basis of CTG safety net criteria than on DV changes. Moreover the somewhat 
poorer outcome in the cCTG group might be explained by absence of a DV safety net in that group, 
whereas the DV groups had a cCTG safety net. You can expect outcomes similar to those of the 
TRUFFLE study only by using DV Doppler and cCTG in conjunction.  
My hospital doesn’t use cCTG, can I use normal CTG? We don’t recommend this. The CTG 
monitoring in the TRUFFLE study was based on computerized assessment of fetal heart short term 
variation (STV). Although there is no randomised trial evidence against visual interpretation, cCTG is 
the only objective measure of fetal heart rate that has been validated against invasive testing in fetal 
hypoxia and acidaemia. Simple visual interpretation of a regular CTG may not be sufficiently 
informative, nor objective enough to provide reassurance about the fetal condition. The cCTG 
equipment used calculated short term variation (STV) based on the Dawes-Redman algorithm. 
Computerised CTG will also detect repetitive fetal heart rate decelerations, although these may also 
be assessed visually. Though we have described other fetal heart rate parameters that may be better 
than STV for assessing fetal condition in severe growth restriction [9], these are not yet evaluated for 
clinical management. 
Given the current interest in the cerebral circulation, should we deliver based on middle cerebral 
artery PI, cerebro-placental ratio or umbilical / middle cerebral artery PI ratio? No. There were 
weak associations between middle cerebral artery Doppler and short term neonatal outcome, and 
MCA and UC ratio with 2-year neurodevelopmental outcome. Although these indices may be 
informative in understanding the pathophysiological process, they are of no proven benefit in the 
monitoring or management strategy before 32 weeks of gestation [7].  
Did neurodevelopmental impairment change with gestational age and was it related to neonatal 
morbidity? An important strength of TRUFFLE is that babies were followed up to the age of 2 years, 
allowing assessment of neurodevelopmental impairment (NDI). The overall rate of NDI was 
10%.  Although neonatal morbidity (NNM) was a risk factor for NDI, in most infants with NDI this was 
not preceded by NNM [10].  
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Bar chart describing rates within  gestational age groups of  severe neonatal morbidity (NNM, a composite of 
one or more of the following severe morbidities: bronchopulmonary dysplasia, severe germinal matrix cerebral 
haemorrhage grades 3 and 4, cystic periventricular leukomalacia, proven neonatal ,  necrotizing 
enterocolitis)  and of neurodevelopmental impairment (NDI, a composite of one or more of the following: a 
cognitive Bayley III score<85, disabling cerebral paresis, hearing loss requiring hearing aids or severe visual loss) 
in surviving children. There were 31 children born at 26-27 weeks, 109 children born at 28-29 weeks, 145 
children born at 30-31 weeks, 80 children born at 32-33 weeks and 37 children born at >33 weeks There was a 
significant relation between NNM and gestational age (p<0.001) , but not between NDI and gestational age 
(p=0.40).  
But many women in the Doppler group were delivered for reasons other than abnormal ductus 
venosus Doppler? 
Yes-that is true: delivery was undertaken for severe pre-eclampsia or HELLP syndrome in 54 (11%) 
women and for fetal distress not based on the study protocol in a further 55 (11%) women. This was 
anticipated in the trial design and does not constitute “off protocol” delivery. Such  occurrences are 
a frequent feature of randomized controlled studies. It is generally recommended to undertake an 
“intention to treat” analysis, in other words, what the intended delivery criteria were rather than 
what the actual reason for delivery was. This is because when the decision is made to monitor an 
individual woman with a certain modality, it is not known what factors will intercede in future. Of 
course, many women were delivered per protocol before 32 weeks, and this included by cCTG 
‘safety net’ indication in the early and late DV groups.  We have detailed these outcomes [4]: there 
was a lower rate of survival without neurodevelopmental impairment in those randomized to CTG 
(which included umbilical artery but not ductus venosus Doppler) than in mothers delivered 
according to ductus venosus changes. The finding that many women deliver for reasons other than 
DV means that CTG, which was integral part of the three arms, is a key component of the monitoring 
strategy and should not be disregarded. 
What about the fact there more fetal deaths in the late ductus group? And is there an explanation 
why neurodevelopmental outcomes were better in survivors within the ductus venosus groups? In 
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total there were 12 fetal deaths, and it is likely the differences in fetal death occurred  between 
groups by chance. Fetal deaths were categorized as unexpected, or due to planned non-
intervention. In total there were 2 fetal deaths in the CTG group, 4 in the early ductus group and 6 in 
the late ductus group. Assessment of the monitoring parameters that were obtained shortly before 
fetal death in the 7 unexpected cases of fetal death showed an abnormal CTG in only 1. Hence 6 out 
of 7 cases would not have been delivered in the other arms of the trial based on monitoring data. 
The other deaths were inevitable (parents declined intervention) or due to congenital abnormality 
(5). The pathophysiological reason why neurodevelopmental outcomes were better in the ductus 
venosus groups is not elucidated by this study. However, we speculate that both CTG and ductus 
venosus Doppler are parameters that indicate (failing) homeostatic mechanisms. Thus, when they 
become abnormal, the balance of risks in intervention and expectant management slides towards 
intervention. 
Do the findings of the study still hold true for babies delivered according to the randomized 
indication before 32 weeks? Yes. Outcomes prior to 32 weeks were significantly better in those 
women randomized to the ductus venosus Doppler groups compared to the CTG group [5]. 
How often should we monitor severe FGR? There is no international consensus on the frequency of 
monitoring in early FGR.  The study by Wolf [8] suggests that unless CTG STV monitoring is 
undertaken daily, there is a 5% risk of missing an abnormally low STV. We do not know whether a 
low STV would have recovered subsequently, and the TRUFFLE study was not intended to define an 
ideal monitoring regimen. Based on these results daily CTG STV may be initiated but given the very 
low risk of intra uterine death in the TRUFFLE cohort alternate day monitoring with CTG STV and 
Doppler is an appropriate minimum, as stated in the protocol agreed through consensus by TRUFFLE 
investigators.  
How can I use the TRUFFLE results for counselling? These two bar charts, taken from the TRUFFLE 
report of perinatal morbidity and mortality analysed as a cohort (2) may be useful in counselling. 
They give the main outcome data split by gestation for both counselling women at study inclusion, 
and then at delivery. For example, if a woman is diagnosed with FGR at 28 weeks, the bar chart ‘at 
inclusion’ is used.  
 
Page 6 of 9
John Wiley & Sons, Ltd.
Ultrasound in Obstetrics and Gynecology
For Peer Review
7 
 
TRUFFLE key messages 4.2 140717 
 
If her pregnancy proceeds to 30 weeks and there is a plan to deliver, the chart ‘at delivery’ can be 
used to update the counselling: 
 
How often should we monitor maternal blood pressure? The TRUFFLE study did not evaluate the 
optimal frequency of blood pressure monitoring. However, we found that 70% of women where 
there was FGR developed gestational hypertension. Based on this it would seem reasonable to 
recommend checking blood pressure and urinary protein:creatinine ratio (or using dip-stick analysis) 
at each visit or at least weekly in asymptomatic women with such severe FGR. 
Some pregnancies continued beyond 32 weeks, what happened to them? They were delivered 
according to the local protocols. In general, this meant delivery was undertaken at 32 weeks if there 
was umbilical reversed EDF, at 34 weeks in absent EDF, and at beyond 34weeks if the umbilical 
artery PI was raised. Delivery for the same criteria at 30, 32 and beyond 32 weeks, respectively, was 
discretionary.  
As the upper gestation age at recruitment to TRUFFLE 1 was 31+6 weeks, the TRUFFLE study cannot 
answer the question as to how best to monitor and when to deliver these slightly later gestation 
babies. The TRUFFLE 2 randomized study under development will test different triggers for delivery 
in women with compromised and/or small babies at 32-37 weeks. 
Schematic: SEE NEW VERSION ATTACHED SEPARATELY 
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Diagnosis of early onset IUGR 
• Singleton fetus  
• 26-32 weeks  
• No obvious anomalies, congenital infection or chromosomal 
defects 
• AC < 10th percentile  
• Umbilical artery Doppler PI > 95th Percentile 
• Positive DV 
• cCTG: 
- 26+0 to <29+0 weeks STV > 2.6 msec;  
- 29+0 to <32+0 weeks STV > 3 msec.  
- No repeated decelerations on CTG.  
Decision for active management? 
Yes: Institute fetal and maternal surveillance 
Measure umbilical artery PI, DV and cCTG 
Maternal monitoring for  pre-eclampsia 
No: manage per local protocol and parental wishes 
Delivery criteria not met:  
Repeat surveillance every 2 days 
Delivery criteria met: 
Delivery after steroid administration 
Asses for delivery criteria: 
Late DV changes  
• A wave at or below baseline twice over 24 h 
cCTG 
• 26+0 to <29+0 weeks STV < 2.6 msec;  
• 29+0 to <32+0 weeks STV< 3 msec.  
• Spontaneous repeated persistent unprovoked 
decelerations.  
Umbilical artery Doppler 
• >32+0 weeks if reversed umbilical artery EDF 
• >34+0 weeks if absent umbilical artery EDF 
Maternal indications 
• Local protocol,  e.g. severe pre-eclampsia, HELLP syndrome 
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